The safety of intravenous iron dextran in hemodialysis patients
- 1 October 1996
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 28 (4), 529-534
- https://doi.org/10.1016/s0272-6386(96)90463-1
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementationAmerican Journal of Kidney Diseases, 1995
- Anaphylactoid Reactions in Dialysis Patients: Pathogenesis and ManagementSeminars in Dialysis, 1995
- The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patientsAmerican Journal of Kidney Diseases, 1995
- Iron and total iron-binding capacity in serum of patients receiving iron-dextran: Kodak Ektachem methodologies, spectrophotometry, and atomic-absorption spectrometry comparedClinical Chemistry, 1990
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- Intravenous iron dextran in clinical medicineJAMA, 1980
- Structure of an iron-dextran complexJournal of Pharmacy and Pharmacology, 1972
- Characteristics of Iron Dextran Utilization in ManBlood, 1969
- Valency Investigations of Iron Dextran (‘Imferon’)Nature, 1965